In another phase I clinical trial, Flt3L was administered for 14 consecutive days monthly to patients with human epidermal growth factor receptor 2 (HER-2/neu)+ breast and ovarian cancers [92]. This evidence concerns the gene ERBB2 and ovarian cancer.